Clinical guidelines for diagnosis, treatment and monitoring of patients with malignant tumors of uterine corpus

Autori:

Ana Fröbe , Blanka Jakšić, Višnja Matković, Herman Haller, Branka Petrić Miše, Dražan Butorac, Goran Vujić, Marina Kos, Tihana Boraska Jelavić, Snježana Tomić, Vanda Paradžik Pašalić, Ante Ćorušić, Ani Mihaljević Ferari, Ivana Canjko, Angela Prgomet Sečan, Danijela Vrdoljak Mozetić, Tanja Leniček, Gordana Lovrenčić-Prpić, Anastazija Aleksandrova Stanojević, Eduard Vrdoljak

Sažetak
Rak tijela maternice, prema zadnjim podatcima Registra za rak iz 2017. godine u Republici Hrvatskoj, nalazi se na četvrtom mjestu po učestalosti, a na osmom mjestu po smrtnosti. Najčešće se dijagnosticira u postmenopauzalnih žena, većinom u dobi od 50. do 79. godine života. Dijagnoza karcinoma endometrija utvrđuje se patohistološkom analizom kiretmana ili bioptata sluznice maternice, a stupanj proširenosti bolesti primjenom slikovnih metoda. U većine bolesnica bolest se otkriva u lokaliziranom stadiju te se uspješno liječi operativno, a ovisno o patohistološkom nalazu i primjenom odgovarajuće adjuvantne terapije. Lokalno uznapredovala bolest najčešće se liječi operativno uz adjuvantnu terapiju, a metastatska primjenom kemoterapije ili hormonske terapije. Mezenhimalni tumori tijela maternice liječe se operativno uz dodatak sistemske terapije adjuvantno ili samo sistemskom terapijom u slučaju diseminirane bolesti. Ove kliničke upute pisane su u cilju postizanja najviših standarda i ujednačenja postupaka u dijagnosticiranju, liječenju i praćenju bolesnica sa zloćudnim tumorima tijela maternice u Republici Hrvatskoj.
Summary

Uterine cancer, according to the latest data from the 2017 Croatian Cancer Registry, is the fourth most common cancer in women in Croatia and ranking eighth in mortality. Most commonly, it is diagnosed in postmenopausal women at the age 50–79. Endometrial cancer diagnosis is determined by pathohistological analysis of curettage or biopsy and the stage of the disease by radiological imaging. In most patients, the disease is diagnosed in the localized stage and is successfully treated surgically; depending on the pathohistological finding, appropriate adjuvant therapy could be applied. Locally advanced disease is most commonly treated surgically
with adjuvant therapy, and metastatic with chemotherapy or hormone therapy. Mesenchymal tumors of the uterine body are treated surgically with the addition of systemic adjuvant therapy, or only systemic therapy in the case of metastatic disease. The following manuscript presents clinical guidelines to standardise procedures for the diagnosis, treatment and follow-up of patients with malignant tumors of the uterus in the Republic of Croatia.

Volumen: 11-12, 2021

Liječ Vjesn 2021;143:404–415

Preuzmi PDF